Expression of bcl-2 in lung neuroendocrine tumours: Comparison with p53

Journal of Pathology

Volumn 184, Issue 3, 1998, Pages 247-251

  Wang, D A Gong ^a,b   Johnston, Colin F ^a   Sloan, James M ^a   Buchanan, Keith D ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b WELLCOME RESEARCH LABORATORIES   (United Kingdom)

Author keywords

Apoptosis; Bcl 2; Lung carcinoid; p53; Small cell lung carcinoma; Tumourigenesis

Indexed keywords

COMPLEMENTARY DNA; PROTEIN BCL 2; PROTEIN P53; RNA;

ADULT; AGED; ARTICLE; CARCINOID; CONTROLLED STUDY; FEMALE; GENETIC COMPLEMENTATION; HUMAN; HUMAN TISSUE; LUNG SMALL CELL CANCER; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARCINOID TUMOR; CARCINOMA, SMALL CELL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEUROENDOCRINE TUMORS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, NEOPLASM; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031915739     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199803)184:3<247::AID-PATH994>3.0.CO;2-P     Document Type: Article

References (36)

1. Bensch KG, Corrin B, Pariente R, Spencer H. Oat-cell carcinoma of the lung. Its origin and relationship to bronchial carcinoid. Cancer (Philadelphia) 1968; 22: 1168-1172.
2. Gould VE, Linnoila I, Menoli VA, Warren WH. Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias, and neoplasms. Lab Invest 1983; 49: 519-537.
3. Godwin JD. Carcinoid tumours. Cancer 1975; 36: 560-569.
4. Arrigoni MG, Wooner LB, Bernatz PE. Atypical carcinoid tumours of the lung. J Thorac Cardiovasc Surg 1972; 64: 413-421.
5. Bishop MJ. Molecular genetics of cancer. Science 1987; 235: 305-311.
6. Willians GT, Smith CA. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993; 74: 777-779.
7. McDonnell TJ. Cell division versus cell death: a functional model of multistep neoplasta. Mol Carcinog 1993; 8: 209-213.
8. Hochenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondria membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
9. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994; 54: 6-8.
10. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 1994; 145: 1036-1040.
11. Jiang SX, Sato Y, Kuwao S, Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 1996; 177: 155-138.
12. Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosis-related factors p53, Bcl-2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996; 149: 1941-1952.
13. Buchanan KD, Johnston CF, O'Hare MMT, et al. Neuroendocrine tumours: a European view. Am J Med 1986; 81: 14-22.
14. Wang DG, Barros D'Sa AAB, Johnston CF, Buchanan KD. Oncogene expression in carotid body tumours. Cancer 1996; 77: 2581-2587.
15. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83: 5214-5218.
16. Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246: 491-494.
17. Lohmann D, Pütz B, Reich U, Böhm J, Präuer H, Höfler H. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am J Pathol 1993; 142: 907-915.
18. Rygaard K, Vindelov LL, Spang-Thomsen M. Expression of myc family oncoproteins in small cell lung cancer cell lines and xenografts. Int J Cancer 1993; 54: 144-152.
19. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879-886.
20. Tsujimoto Y. Stress-resistance conferred by high level of bcl-2α protein in human B lymphoblastoid cell. Oncogene 1989; 4: 1331-1336.
21. Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compound in differentiation-competent and defective myeloid leukaemia cells. Cell Growth Differ 1993; 4: 41-47.
22. Sentman CJ, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67: 879-888.
23. Strasser A, Harris AW, Cory S. bcl-2 transgene inhibits cell death and perturbs thymic self-censorship. Cell 1991; 67: 889-899.
24. Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI 7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992; 52: 5407-5411.
25. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemia cells that is inhibited by interleukin-6. Nature 1991; 352: 345-347.
26. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119-128.
27. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 1993; 329: 690-694.
28. Ohmori T, Podack E, Nishio K, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by BCL-2. Biochem Biophys Res Commun 1993; 192: 30-36.
29. Minna JD, Pass H, Galstein E, Ihde D. Cancer of the lung. In: Devia T, Helman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology. Philadelphia: J. B. Lippincott, 1989; 591-705.
30. Gorczyca W, Markiewski M, Kram A, Tuziak T, Domagala W. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Virchows Arch 1995; 426: 299-233.
31. Sinicrope FA, Ruan SB, Cleary KB, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumourigenesis. Cancer Res 1995; 55: 237-241.
32. Bosari S, Moneghini L, Graziani D, et al. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol 1995; 26: 534-540.
33. Wang DG, Johnston CF, Anderson N, Sloan JM, Buchanan KD. Over-expression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis. J Pathol 1995; 175: 397-401.
34. Lohmann DR, Fesseler B, Pütz B, et al. Infrequent mutations of the p53 gene in pulmonary carcinoid tumours. Cancer Res 1993; 53: 5797-5801.
35. Vaux DL, Cory S, Adama JM. bcl-2 gene promotes haemopoietic cell survival and co-operates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
36. McDonnell TJ, Deane N, Platt FM, et al. bcl-2 immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88.